WINTON GROUP Ltd Buys Shares of 2,569 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

WINTON GROUP Ltd purchased a new position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,569 shares of the company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in PROCEPT BioRobotics by 13.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 402,565 shares of the company’s stock valued at $32,254,000 after acquiring an additional 46,665 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of PROCEPT BioRobotics by 34.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,316 shares of the company’s stock worth $1,067,000 after purchasing an additional 3,403 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of PROCEPT BioRobotics by 2.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,460 shares of the company’s stock valued at $9,331,000 after purchasing an additional 3,083 shares during the last quarter. PEAK6 Investments LLC purchased a new position in shares of PROCEPT BioRobotics during the 3rd quarter valued at about $353,000. Finally, Verition Fund Management LLC bought a new stake in PROCEPT BioRobotics in the 3rd quarter worth approximately $2,132,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,455 shares of company stock worth $368,322. 17.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on PRCT. Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Truist Financial reiterated a “buy” rating and issued a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Finally, Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $94.29.

PROCEPT BioRobotics Stock Down 3.0 %

Shares of PROCEPT BioRobotics stock opened at $58.26 on Tuesday. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -29.88 and a beta of 1.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company’s 50 day moving average price is $64.98 and its 200-day moving average price is $77.66. PROCEPT BioRobotics Co. has a 52-week low of $45.56 and a 52-week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $68.24 million for the quarter, compared to analysts’ expectations of $66.79 million. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).